Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health, Inc. (NASDAQ: OPK) reported its financial results for Q1 2022, revealing consolidated revenues of $329.2 million, down from $545.2 million in Q1 2021. The company incurred a net loss of $55.4 million, or $0.08 per share, compared to a net income of $31.1 million in the previous year. Key business highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and the sale of GeneDx to Sema4, which provided $150 million in cash proceeds. Notably, OPKO expects to receive $85 million in milestone payments from Pfizer in Q2 2022.
OPKO Health, Inc. (NASDAQ: OPK) has acquired ModeX Therapeutics for $300 million in OPKO common stock, significantly enhancing its product pipeline. Notable appointments include Dr. Elias Zerhouni as President and Vice Chairman, Dr. Gary Nabel as Chief Innovation Officer, and Alexis Borisy as a Board member. ModeX specializes in innovative immune therapies for cancer and infectious diseases using multi-specific antibody technologies. This acquisition aims to leverage synergies in OPKO's diagnostics and therapeutics portfolio, potentially improving patient outcomes and accelerating product development.
OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. The company's senior management will discuss the results and provide financial guidance during a live conference call at 4:30 PM ET. Participants can pre-register for the call and access a webcast on OPKO's Investor Relations page. A replay will be available until May 16, 2022. For further information about OPKO's operations and market position, visit their official website.
GeneDx, Inc. has published research highlighting the importance of genomic data sharing for identifying gene-disease relationships. This initiative, facilitated through GeneMatcher, has resulted in over 200 new associations of disease-gene links in just three years. The findings were published in Human Mutation, demonstrating how collaboration between clinicians and researchers can accelerate diagnosis for rare diseases. GeneDx's extensive database of over 300,000 clinical exomes plays a crucial role in these developments, significantly impacting patient diagnostics and advancing precision medicine.
Saol Therapeutics has announced a collaboration with GeneDx to identify patients with Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare mitochondrial disease affecting fewer than 300 children annually in the U.S. The partnership aims to increase recruitment for a Phase 3 clinical trial testing dichloroacetate (DCA), which has Orphan Product designation from the FDA for congenital lactic acidosis. The trial is crucial as PDCD currently lacks FDA-approved treatments. Dr. Peter Stacpoole emphasizes the importance of the collaboration for effective patient recruitment.
OPKO Health, Inc. (NASDAQ: OPK) announced its fourth quarter 2021 financial results with total revenues of $401.3 million, down from $494.6 million in Q4 2020. The company reported a net loss of $73.8 million, or $0.11 per share, compared to net income of $32.3 million a year prior. Key highlights include NGENLA® receiving regulatory approvals in multiple countries and RAYALDEE® launched in Germany. OPKO has entered a definitive agreement for Sema4 to acquire GeneDx for a potential total consideration of $623 million.
OPKO Health, Inc. (NASDAQ: OPK) is set to release its financial results for the quarter ended December 31, 2021, post-market on February 24, 2022. The company will also provide a business update and financial guidance during a conference call at 4:30 p.m. Eastern on the same day. Investors can pre-register for the call or access it via a live audio webcast. The call aims to discuss operating metrics and future outlook. For more details about OPKO's strategies and market position, visit their website.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received EU marketing authorization for NGENLA™ (somatrogon), a long-acting growth hormone replacement therapy for children with growth hormone deficiency (GHD). This innovative treatment reduces injection frequency from daily to weekly, potentially enhancing patient adherence and quality of life. The approval is based on the positive results from a Phase 3 study demonstrating NGENLA's non-inferiority to GENOTROPIN® (somatropin) in height velocity. NGENLA is now available across all EU states, Iceland, Norway, and Liechtenstein.
OPKO Health, Inc. (NASDAQ: OPK) announces the launch of RAYALDEE® in Germany, marking the first international release of the extended-release calcifediol product. Vifor Fresenius Medical Care Renal Pharma (VFMCRP), OPKO's partner, plans to expand the rollout across 11 European countries with Switzerland next in line. RAYALDEE is indicated for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency, addressing a significant market opportunity in Europe, where about 26 million people are affected.
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) received a Complete Response Letter (CRL) from the FDA concerning their Biologics License Application for somatrogon, a once-weekly treatment for pediatric growth hormone deficiency (GHD). Pfizer will collaborate with the FDA to address the feedback. Despite the setback, somatrogon has gained approvals in several countries, including Japan, Canada, and Australia. The European Commission decision is expected soon. The companies remain committed to advancing somatrogon and addressing unmet medical needs in GHD.